ID   SRC_HUMAN               Reviewed;         536 AA.
AC   P12931; E1P5V4; Q76P87; Q86VB9; Q9H5A8;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   10-MAY-2017, entry version 218.
DE   RecName: Full=Proto-oncogene tyrosine-protein kinase Src;
DE            EC=2.7.10.2;
DE   AltName: Full=Proto-oncogene c-Src;
DE   AltName: Full=pp60c-src;
DE            Short=p60-Src;
GN   Name=SRC; Synonyms=SRC1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-185 (ISOFORM 1).
RX   PubMed=3299057; DOI=10.1128/MCB.7.5.1978;
RA   Tanaka A., Gibbs C.P., Arthur R.R., Anderson S.K., Kung H.-J.,
RA   Fujita D.J.;
RT   "DNA sequence encoding the amino-terminal region of the human c-src
RT   protein: implications of sequence divergence among src-type kinase
RT   oncogenes.";
RL   Mol. Cell. Biol. 7:1978-1983(1987).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 186-536 (ISOFORM 1).
RX   PubMed=2582238; DOI=10.1128/MCB.5.5.1122;
RA   Anderson S.K., Gibbs C.P., Tanaka A., Kung H.-J., Fujita D.J.;
RT   "Human cellular src gene: nucleotide sequence and derived amino acid
RT   sequence of the region coding for the carboxy-terminal two-thirds of
RT   pp60c-src.";
RL   Mol. Cell. Biol. 5:1122-1129(1985).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 98-139 (ISOFORM 2).
RX   PubMed=2681803; DOI=10.1002/jnr.490240113;
RA   Pyper J.M., Bolen J.B.;
RT   "Neuron-specific splicing of C-SRC RNA in human brain.";
RL   J. Neurosci. Res. 24:89-96(1989).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 376-536 (ISOFORM 1).
RX   PubMed=2581127; DOI=10.1128/MCB.5.4.831;
RA   Parker R.C., Mardon G., Lebo R.V., Varmus H.E., Bishop J.M.;
RT   "Isolation of duplicated human c-src genes located on chromosomes 1
RT   and 20.";
RL   Mol. Cell. Biol. 5:831-838(1985).
RN   [8]
RP   PHOSPHORYLATION AT TYR-419.
RX   PubMed=6273838; DOI=10.1073/pnas.78.10.6013;
RA   Smart J.E., Oppermann H., Czernilofsky A.P., Purchio A.F.,
RA   Erikson R.L., Bishop J.M.;
RT   "Characterization of sites for tyrosine phosphorylation in the
RT   transforming protein of Rous sarcoma virus (pp60v-src) and its normal
RT   cellular homologue (pp60c-src).";
RL   Proc. Natl. Acad. Sci. U.S.A. 78:6013-6017(1981).
RN   [9]
RP   ROLE IN TUMOR TISSUES.
RX   PubMed=3093483;
RA   Rosen N., Bolen J.B., Schwartz A.M., Cohen P., DeSeau V., Israel M.A.;
RT   "Analysis of pp60c-src protein kinase activity in human tumor cell
RT   lines and tissues.";
RL   J. Biol. Chem. 261:13754-13759(1986).
RN   [10]
RP   ROLE IN COLON CARCINOMA.
RX   PubMed=2498394; DOI=10.1172/JCI114113;
RA   Cartwright C.A., Kamps M.P., Meisler A.I., Pipas J.M., Eckhart W.;
RT   "pp60c-src activation in human colon carcinoma.";
RL   J. Clin. Invest. 83:2025-2033(1989).
RN   [11]
RP   ALTERNATIVE SPLICING.
RX   PubMed=1691439; DOI=10.1128/MCB.10.5.2035;
RA   Pyper J.M., Bolen J.B.;
RT   "Identification of a novel neuronal C-SRC exon expressed in human
RT   brain.";
RL   Mol. Cell. Biol. 10:2035-2040(1990).
RN   [12]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-530, AND MYRISTOYLATION
RP   AT GLY-2.
RX   PubMed=7525268;
RA   Kaplan K.B., Bibbins K.B., Swedlow J.R., Arnaud M., Morgan D.O.,
RA   Varmus H.E.;
RT   "Association of the amino-terminal half of c-Src with focal adhesions
RT   alters their properties and is regulated by phosphorylation of
RT   tyrosine 527.";
RL   EMBO J. 13:4745-4756(1994).
RN   [13]
RP   PHOSPHORYLATION, AND ENZYME REGULATION.
RX   PubMed=7929427;
RA   Stover D.R., Liebetanz J., Lydon N.B.;
RT   "Cdc2-mediated modulation of pp60c-src activity.";
RL   J. Biol. Chem. 269:26885-26889(1994).
RN   [14]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=7853507;
RA   David-Pfeuty T., Nouvian-Dooghe Y.;
RT   "Highly specific antibody to Rous sarcoma virus src gene product
RT   recognizes nuclear and nucleolar antigens in human cells.";
RL   J. Virol. 69:1699-1713(1995).
RN   [15]
RP   INTERACTION WITH CEACAM1.
RX   PubMed=7478590;
RA   Bruemmer J., Neumaier M., Goepfert C., Wagener C.;
RT   "Association of pp60c-src with biliary glycoprotein (CD66a), an
RT   adhesion molecule of the carcinoembryonic antigen family downregulated
RT   in colorectal carcinomas.";
RL   Oncogene 11:1649-1655(1995).
RN   [16]
RP   INTERACTION WITH FCAMR, ENZYME REGULATION, AND FUNCTION.
RX   PubMed=8759729;
RA   Rabinowich H., Manciulea M., Metes D., Sulica A., Herberman R.B.,
RA   Corey S.J., Whiteside T.L.;
RT   "Physical and functional association of Fc mu receptor on human
RT   natural killer cells with the zeta- and Fc epsilon RI gamma-chains and
RT   with src family protein tyrosine kinases.";
RL   J. Immunol. 157:1485-1491(1996).
RN   [17]
RP   FUNCTION IN HGF SIGNALING PATHWAY.
RX   PubMed=8755529; DOI=10.1073/pnas.93.15.7644;
RA   Grano M., Galimi F., Zambonin G., Colucci S., Cottone E.,
RA   Zallone A.Z., Comoglio P.M.;
RT   "Hepatocyte growth factor is a coupling factor for osteoclasts and
RT   osteoblasts in vitro.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:7644-7648(1996).
RN   [18]
RP   ENZYME REGULATION.
RX   PubMed=9571170; DOI=10.1006/bbrc.1998.8452;
RA   Yang E.B., Zhang K., Cheng L.Y., Mack P.;
RT   "Butein, a specific protein tyrosine kinase inhibitor.";
RL   Biochem. Biophys. Res. Commun. 245:435-438(1998).
RN   [19]
RP   INTERACTION WITH RACK1.
RX   PubMed=9584165; DOI=10.1128/MCB.18.6.3245;
RA   Chang B.Y., Conroy K.B., Machleder E.M., Cartwright C.A.;
RT   "RACK1, a receptor for activated C kinase and a homolog of the beta
RT   subunit of G proteins, inhibits activity of src tyrosine kinases and
RT   growth of NIH 3T3 cells.";
RL   Mol. Cell. Biol. 18:3245-3256(1998).
RN   [20]
RP   INTERACTION WITH ADRB2 AND ARRB1.
RX   PubMed=9924018; DOI=10.1126/science.283.5402.655;
RA   Luttrell L.M., Ferguson S.S.G., Daaka Y., Miller W.E., Maudsley S.,
RA   Della Rocca G.J., Lin F.-T., Kawakatsu H., Owada K., Luttrell D.K.,
RA   Caron M.G., Lefkowitz R.J.;
RT   "Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src
RT   protein kinase complexes.";
RL   Science 283:655-661(1999).
RN   [21]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=10753943; DOI=10.1074/jbc.275.15.11312;
RA   Miller W.E., Maudsley S., Ahn S., Khan K.D., Luttrell L.M.,
RA   Lefkowitz R.J.;
RT   "beta-arrestin1 interacts with the catalytic domain of the tyrosine
RT   kinase c-SRC. Role of beta-arrestin1-dependent targeting of c-SRC in
RT   receptor endocytosis.";
RL   J. Biol. Chem. 275:11312-11319(2000).
RN   [22]
RP   INTERACTION WITH RALGPS1.
RX   PubMed=10747847; DOI=10.1074/jbc.C000085200;
RA   Rebhun J.F., Chen H., Quilliam L.A.;
RT   "Identification and characterization of a new family of guanine
RT   nucleotide exchange factors for the ras-related GTPase Ral.";
RL   J. Biol. Chem. 275:13406-13410(2000).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF RASA1 AND RASGRF1.
RX   PubMed=11389730; DOI=10.1046/j.1432-1327.2001.02230.x;
RA   Giglione C., Gonfloni S., Parmeggiani A.;
RT   "Differential actions of p60c-Src and Lck kinases on the Ras
RT   regulators p120-GAP and GDP/GTP exchange factor CDC25Mm.";
RL   Eur. J. Biochem. 268:3275-3283(2001).
RN   [24]
RP   INTERACTION WITH MUC1.
RX   PubMed=11152665; DOI=10.1074/jbc.C000754200;
RA   Li Y., Kuwahara H., Ren J., Wen G., Kufe D.;
RT   "The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1
RT   carcinoma-associated antigen with GSK3 beta and beta-catenin.";
RL   J. Biol. Chem. 276:6061-6064(2001).
RN   [25]
RP   INTERACTION WITH RACK1.
RX   PubMed=11279199; DOI=10.1074/jbc.M101375200;
RA   Chang B.Y., Chiang M., Cartwright C.A.;
RT   "The interaction of Src and RACK1 is enhanced by activation of protein
RT   kinase C and tyrosine phosphorylation of RACK1.";
RL   J. Biol. Chem. 276:20346-20356(2001).
RN   [26]
RP   INTERACTION WITH HEV ORF3 PROTEIN.
RX   PubMed=11518702; DOI=10.1074/jbc.M101546200;
RA   Korkaya H., Jameel S., Gupta D., Tyagi S., Kumar R., Zafrullah M.,
RA   Mazumdar M., Lal S.K., Xiaofang L., Sehgal D., Das S.R., Sahal D.;
RT   "The ORF3 protein of hepatitis E virus binds to Src homology 3 domains
RT   and activates MAPK.";
RL   J. Biol. Chem. 276:42389-42400(2001).
RN   [27]
RP   INTERACTION WITH CAV2.
RX   PubMed=12091389; DOI=10.1074/jbc.M204367200;
RA   Lee H., Park D.S., Wang X.B., Scherer P.E., Schwartz P.E.,
RA   Lisanti M.P.;
RT   "Src-induced phosphorylation of caveolin-2 on tyrosine 19. Phospho-
RT   caveolin-2 (Tyr(P)19) is localized near focal adhesions, remains
RT   associated with lipid rafts/caveolae, but no longer forms a high
RT   molecular mass hetero-oligomer with caveolin-1.";
RL   J. Biol. Chem. 277:34556-34567(2002).
RN   [28]
RP   INTERACTION WITH PELP1.
RX   PubMed=12415108; DOI=10.1073/pnas.192569699;
RA   Wong C.-W., McNally C., Nickbarg E., Komm B.S., Cheskis B.J.;
RT   "Estrogen receptor-interacting protein that modulates its nongenomic
RT   activity-crosstalk with Src/Erk phosphorylation cascade.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:14783-14788(2002).
RN   [29]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12615910; DOI=10.1083/jcb.200209098;
RA   Miyazaki T., Neff L., Tanaka S., Horne W.C., Baron R.;
RT   "Regulation of cytochrome c oxidase activity by c-Src in
RT   osteoclasts.";
RL   J. Cell Biol. 160:709-718(2003).
RN   [30]
RP   INTERACTION WITH EPHB1.
RX   PubMed=12925710; DOI=10.1083/jcb.200302073;
RA   Vindis C., Cerretti D.P., Daniel T.O., Huynh-Do U.;
RT   "EphB1 recruits c-Src and p52Shc to activate MAPK/ERK and promote
RT   chemotaxis.";
RL   J. Cell Biol. 162:661-671(2003).
RN   [31]
RP   ENZYME REGULATION.
RX   PubMed=14632929; DOI=10.1046/j.1399-3011.2003.00094.x;
RA   Kamath J.R., Liu R., Enstrom A.M., Lou Q., Lam K.S.;
RT   "Development and characterization of potent and specific peptide
RT   inhibitors of p60c-src protein tyrosine kinase using pseudosubstrate-
RT   based inhibitor design approach.";
RL   J. Pept. Res. 62:260-268(2003).
RN   [32]
RP   FUNCTION IN PHOSPHORYLATION OF PDPK1, AND INTERACTION WITH PTK2B/PYK2.
RX   PubMed=14585963; DOI=10.1128/MCB.23.22.8019-8029.2003;
RA   Taniyama Y., Weber D.S., Rocic P., Hilenski L., Akers M.L., Park J.,
RA   Hemmings B.A., Alexander R.W., Griendling K.K.;
RT   "Pyk2- and Src-dependent tyrosine phosphorylation of PDK1 regulates
RT   focal adhesions.";
RL   Mol. Cell. Biol. 23:8019-8029(2003).
RN   [33]
RP   INTERACTION WITH CAV2.
RX   PubMed=15504032; DOI=10.1021/bi049295+;
RA   Wang X.B., Lee H., Capozza F., Marmon S., Sotgia F., Brooks J.W.,
RA   Campos-Gonzalez R., Lisanti M.P.;
RT   "Tyrosine phosphorylation of caveolin-2 at residue 27: differences in
RT   the spatial and temporal behavior of phospho-Cav-2 (pY19 and pY27).";
RL   Biochemistry 43:13694-13706(2004).
RN   [34]
RP   INTERACTION WITH CBCLC, PHOSPHORYLATION AT TYR-419, AND MUTAGENESIS OF
RP   LYS-298.
RX   PubMed=14661060; DOI=10.1038/sj.onc.1207298;
RA   Kim M., Tezuka T., Tanaka K., Yamamoto T.;
RT   "Cbl-c suppresses v-Src-induced transformation through ubiquitin-
RT   dependent protein degradation.";
RL   Oncogene 23:1645-1655(2004).
RN   [35]
RP   INTERACTION WITH CDCP1.
RX   PubMed=15851033; DOI=10.1016/j.cell.2005.02.019;
RA   Benes C.H., Wu N., Elia A.E.H., Dharia T., Cantley L.C., Soltoff S.P.;
RT   "The C2 domain of PKCdelta is a phosphotyrosine binding domain.";
RL   Cell 121:271-280(2005).
RN   [36]
RP   FUNCTION IN PHOSPHORYLATION OF DDR2.
RX   PubMed=16186108; DOI=10.1074/jbc.M506921200;
RA   Yang K., Kim J.H., Kim H.J., Park I.S., Kim I.Y., Yang B.S.;
RT   "Tyrosine 740 phosphorylation of discoidin domain receptor 2 by Src
RT   stimulates intramolecular autophosphorylation and Shc signaling
RT   complex formation.";
RL   J. Biol. Chem. 280:39058-39066(2005).
RN   [37]
RP   INTERACTION WITH TOM1L2.
RX   PubMed=16479011; DOI=10.1128/MCB.26.5.1932-1947.2006;
RA   Franco M., Furstoss O., Simon V., Benistant C., Hong W.J., Roche S.;
RT   "The adaptor protein Tom1L1 is a negative regulator of Src mitogenic
RT   signaling induced by growth factors.";
RL   Mol. Cell. Biol. 26:1932-1947(2006).
RN   [38]
RP   INTERACTION WITH TGFB1I1.
RX   PubMed=17202804; DOI=10.1159/000098402;
RA   Maudsley S., Davidson L., Pawson A.J., Freestone S.H.,
RA   Lopez de Maturana R., Thomson A.A., Millar R.P.;
RT   "Gonadotropin-releasing hormone functionally antagonizes testosterone
RT   activation of the human androgen receptor in prostate cells through
RT   focal adhesion complexes involving Hic-5.";
RL   Neuroendocrinology 84:285-300(2006).
RN   [39]
RP   INTERACTION WITH AMOTL2.
RX   PubMed=17293535; DOI=10.1242/dev.02782;
RA   Huang H., Lu F.I., Jia S., Meng S., Cao Y., Wang Y., Ma W., Yin K.,
RA   Wen Z., Peng J., Thisse C., Thisse B., Meng A.;
RT   "Amotl2 is essential for cell movements in zebrafish embryo and
RT   regulates c-Src translocation.";
RL   Development 134:979-988(2007).
RN   [40]
RP   INTERACTION WITH SRCIN1.
RX   PubMed=17525734; DOI=10.1038/sj.emboj.7601724;
RA   Di Stefano P., Damiano L., Cabodi S., Aramu S., Tordella L.,
RA   Praduroux A., Piva R., Cavallo F., Forni G., Silengo L., Tarone G.,
RA   Turco E., Defilippi P.;
RT   "p140Cap protein suppresses tumour cell properties, regulating Csk and
RT   Src kinase activity.";
RL   EMBO J. 26:2843-2855(2007).
RN   [41]
RP   FUNCTION.
RX   PubMed=18586953; DOI=10.1152/ajplung.90282.2008;
RA   Jeulin C., Seltzer V., Bailbe D., Andreau K., Marano F.;
RT   "EGF mediates calcium-activated chloride channel activation in the
RT   human bronchial epithelial cell line 16HBE14o-: involvement of
RT   tyrosine kinase p60c-src.";
RL   Am. J. Physiol. 295:L489-L496(2008).
RN   [42]
RP   INTERACTION WITH PDPK1.
RX   PubMed=18024423; DOI=10.1074/jbc.M706361200;
RA   Yang K.J., Shin S., Piao L., Shin E., Li Y., Park K.A., Byun H.S.,
RA   Won M., Hong J., Kweon G.R., Hur G.M., Seok J.H., Chun T.,
RA   Brazil D.P., Hemmings B.A., Park J.;
RT   "Regulation of 3-phosphoinositide-dependent protein kinase-1 (PDK1) by
RT   Src involves tyrosine phosphorylation of PDK1 and Src homology 2
RT   domain binding.";
RL   J. Biol. Chem. 283:1480-1491(2008).
RN   [43]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-17, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [44]
RP   INTERACTION WITH PTK2/FAK1; PI3KR1/2 AND ESR1.
RX   PubMed=18657504; DOI=10.1016/j.molcel.2008.05.025;
RA   Le Romancer M., Treilleux I., Leconte N., Robin-Lespinasse Y.,
RA   Sentis S., Bouchekioua-Bouzaghou K., Goddard S., Gobert-Gosse S.,
RA   Corbo L.;
RT   "Regulation of estrogen rapid signaling through arginine methylation
RT   by PRMT1.";
RL   Mol. Cell 31:212-221(2008).
RN   [45]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [46]
RP   INTERACTION WITH FASLG.
RX   PubMed=19807924; DOI=10.1186/1471-2172-10-53;
RA   Voss M., Lettau M., Janssen O.;
RT   "Identification of SH3 domain interaction partners of human FasL
RT   (CD178) by phage display screening.";
RL   BMC Immunol. 10:53-53(2009).
RN   [47]
RP   INTERACTION WITH MPP2.
RX   PubMed=19665017; DOI=10.1016/j.yexcr.2009.07.028;
RA   Baumgartner M., Weiss A., Fritzius T., Heinrich J., Moelling K.;
RT   "The PDZ protein MPP2 interacts with c-Src in epithelial cells.";
RL   Exp. Cell Res. 315:2888-2898(2009).
RN   [48]
RP   FUNCTION, AND INTERACTION WITH TRAF3; MAVS; DDX58 AND TBK1.
RX   PubMed=19419966; DOI=10.1074/jbc.M808233200;
RA   Johnsen I.B., Nguyen T.T., Bergstroem B., Fitzgerald K.A.,
RA   Anthonsen M.W.;
RT   "The tyrosine kinase c-Src enhances RIG-I (retinoic acid-inducible
RT   gene I)-elicited antiviral signaling.";
RL   J. Biol. Chem. 284:19122-19131(2009).
RN   [49]
RP   PHOSPHORYLATION AT TYR-419, AND DEPHOSPHORYLATION AT TYR-419 BY PTPRJ.
RX   PubMed=18936167; DOI=10.1128/MCB.01374-08;
RA   Chabot C., Spring K., Gratton J.P., Elchebly M., Royal I.;
RT   "New role for the protein tyrosine phosphatase DEP-1 in Akt activation
RT   and endothelial cell survival.";
RL   Mol. Cell. Biol. 29:241-253(2009).
RN   [50]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-17 AND TYR-530, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [51]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [52]
RP   ENZYME REGULATION.
RX   PubMed=21036157; DOI=10.1016/j.bbrc.2010.10.101;
RA   Yao X., Balamurugan P., Arvey A., Leslie C., Zhang L.;
RT   "Heme controls the regulation of protein tyrosine kinases Jak2 and
RT   Src.";
RL   Biochem. Biophys. Res. Commun. 403:30-35(2010).
RN   [53]
RP   FUNCTION, AND INTERACTION WITH RUNX3.
RX   PubMed=20100835; DOI=10.1074/jbc.M109.071381;
RA   Goh Y.M., Cinghu S., Hong E.T., Lee Y.S., Kim J.H., Jang J.W.,
RA   Li Y.H., Chi X.Z., Lee K.S., Wee H., Ito Y., Oh B.C., Bae S.C.;
RT   "Src kinase phosphorylates RUNX3 at tyrosine residues and localizes
RT   the protein in the cytoplasm.";
RL   J. Biol. Chem. 285:10122-10129(2010).
RN   [54]
RP   FUNCTION IN CBLC PHOSPHORYLATION.
RX   PubMed=20525694; DOI=10.1074/jbc.M109.091157;
RA   Ryan P.E., Sivadasan-Nair N., Nau M.M., Nicholas S., Lipkowitz S.;
RT   "The N terminus of Cbl-c regulates ubiquitin ligase activity by
RT   modulating affinity for the ubiquitin-conjugating enzyme.";
RL   J. Biol. Chem. 285:23687-23698(2010).
RN   [55]
RP   INTERACTION WITH NDFIP1 AND NDFIP2.
RX   PubMed=20534535; DOI=10.1073/pnas.0911714107;
RA   Mund T., Pelham H.R.;
RT   "Regulation of PTEN/Akt and MAP kinase signaling pathways by the
RT   ubiquitin ligase activators Ndfip1 and Ndfip2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:11429-11434(2010).
RN   [56]
RP   FUNCTION, AND INTERACTION WITH TNK2.
RX   PubMed=21309750; DOI=10.1042/BJ20102156;
RA   Chan W., Sit S.T., Manser E.;
RT   "The Cdc42-associated kinase ACK1 is not auto-inhibited but requires
RT   Src for activation.";
RL   Biochem. J. 435:355-364(2011).
RN   [57]
RP   PHOSPHORYLATION AT SER-75.
RX   PubMed=21442427; DOI=10.1007/s00018-011-0638-1;
RA   Pan Q., Qiao F., Gao C., Norman B., Optican L., Zelenka P.S.;
RT   "Cdk5 targets active Src for ubiquitin-dependent degradation by
RT   phosphorylating Src(S75).";
RL   Cell. Mol. Life Sci. 68:3425-3436(2011).
RN   [58]
RP   REVIEW ON FUNCTION.
RX   PubMed=8672527; DOI=10.1016/0304-419X(96)00003-0;
RA   Brown M.T., Cooper J.A.;
RT   "Regulation, substrates and functions of src.";
RL   Biochim. Biophys. Acta 1287:121-149(1996).
RN   [59]
RP   REVIEW ON FUNCTION.
RX   PubMed=9442882; DOI=10.1146/annurev.cellbio.13.1.513;
RA   Thomas S.M., Brugge J.S.;
RT   "Cellular functions regulated by Src family kinases.";
RL   Annu. Rev. Cell Dev. Biol. 13:513-609(1997).
RN   [60]
RP   REVIEW ON FUNCTION.
RX   PubMed=11964124; DOI=10.1007/s00018-002-8438-2;
RA   Ma Y.C., Huang X.Y.;
RT   "Novel regulation and function of Src tyrosine kinase.";
RL   Cell. Mol. Life Sci. 59:456-462(2002).
RN   [61]
RP   FUNCTION IN FOCAL ADHESION DYNAMICS, AND INTERACTION WITH PTK2/FAK1
RP   AND DNM2.
RX   PubMed=21411625; DOI=10.1091/mbc.E10-09-0785;
RA   Wang Y., Cao H., Chen J., McNiven M.A.;
RT   "A direct interaction between the large GTPase dynamin-2 and FAK
RT   regulates focal adhesion dynamics in response to active Src.";
RL   Mol. Biol. Cell 22:1529-1538(2011).
RN   [62]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-17 AND SER-75, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [63]
RP   FUNCTION IN PHOSPHORYLATION OF BCAR1.
RX   PubMed=22710723; DOI=10.1038/onc.2012.220;
RA   Zhang P., Guo A., Possemato A., Wang C., Beard L., Carlin C.,
RA   Markowitz S.D., Polakiewicz R.D., Wang Z.;
RT   "Identification and functional characterization of p130Cas as a
RT   substrate of protein tyrosine phosphatase nonreceptor 14.";
RL   Oncogene 32:2087-2095(2013).
RN   [64]
RP   INTERACTION WITH TRAP1.
RX   PubMed=23564345; DOI=10.1073/pnas.1220659110;
RA   Yoshida S., Tsutsumi S., Muhlebach G., Sourbier C., Lee M.J., Lee S.,
RA   Vartholomaiou E., Tatokoro M., Beebe K., Miyajima N., Mohney R.P.,
RA   Chen Y., Hasumi H., Xu W., Fukushima H., Nakamura K., Koga F.,
RA   Kihara K., Trepel J., Picard D., Neckers L.;
RT   "Molecular chaperone TRAP1 regulates a metabolic switch between
RT   mitochondrial respiration and aerobic glycolysis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:E1604-E1612(2013).
RN   [65]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-17, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [66]
RP   PHOSPHORYLATION AT TYR-419 AND TYR-530, INVOLVEMENT IN THC6, VARIANT
RP   THC6 LYS-527, AND CHARACTERIZATION OF VARIANT THC6 LYS-527.
RX   PubMed=26936507; DOI=10.1126/scitranslmed.aad7666;
RG   BRIDGE-BPD Consortium;
RA   Turro E., Greene D., Wijgaerts A., Thys C., Lentaigne C.,
RA   Bariana T.K., Westbury S.K., Kelly A.M., Selleslag D., Stephens J.C.,
RA   Papadia S., Simeoni I., Penkett C.J., Ashford S., Attwood A.,
RA   Austin S., Bakchoul T., Collins P., Deevi S.V., Favier R.,
RA   Kostadima M., Lambert M.P., Mathias M., Millar C.M., Peerlinck K.,
RA   Perry D.J., Schulman S., Whitehorn D., Wittevrongel C., De Maeyer M.,
RA   Rendon A., Gomez K., Erber W.N., Mumford A.D., Nurden P., Stirrups K.,
RA   Bradley J.R., Raymond F.L., Laffan M.A., Van Geet C., Richardson S.,
RA   Freson K., Ouwehand W.H.;
RT   "A dominant gain-of-function mutation in universal tyrosine kinase SRC
RT   causes thrombocytopenia, myelofibrosis, bleeding, and bone
RT   pathologies.";
RL   Sci. Transl. Med. 8:328RA30-328RA30(2016).
RN   [67]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 86-536.
RX   PubMed=9024657; DOI=10.1038/385595a0;
RA   Xu W., Harrison S.C., Eck M.J.;
RT   "Three-dimensional structure of the tyrosine kinase c-Src.";
RL   Nature 385:595-602(1997).
RN   [68]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 145-249.
RX   PubMed=9174343; DOI=10.1021/bi970019n;
RA   Charifson P.S., Shewchuk L.M., Rocque W., Hummel C.W., Jordan S.R.,
RA   Mohr C., Pacofsky G.J., Peel M.R., Rodriguez M., Sternbach D.D.,
RA   Consler T.G.;
RT   "Peptide ligands of pp60(c-src) SH2 domains: a thermodynamic and
RT   structural study.";
RL   Biochemistry 36:6283-6293(1997).
RN   [69]
RP   STRUCTURE BY NMR OF 204-249.
RX   PubMed=7532003; DOI=10.1021/bi00007a003;
RA   Xu R.X., Word J.M., Davis D.G., Rink M.J., Willard D.H. Jr.,
RA   Gampe R.T. Jr.;
RT   "Solution structure of the human pp60c-src SH2 domain complexed with a
RT   phosphorylated tyrosine pentapeptide.";
RL   Biochemistry 34:2107-2121(1995).
RN   [70]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 412-424 IN COMPLEX WITH
RP   CBLC, UBIQUITINATION, AND INTERACTION WITH CBLC.
RX   PubMed=22888118; DOI=10.1093/jb/mvs085;
RA   Takeshita K., Tezuka T., Isozaki Y., Yamashita E., Suzuki M., Kim M.,
RA   Yamanashi Y., Yamamoto T., Nakagawa A.;
RT   "Structural flexibility regulates phosphopeptide-binding activity of
RT   the tyrosine kinase binding domain of Cbl-c.";
RL   J. Biochem. 152:487-495(2012).
RN   [71]
RP   VARIANT [LARGE SCALE ANALYSIS] THR-237.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor protein tyrosine kinase which is activated
CC       following engagement of many different classes of cellular
CC       receptors including immune response receptors, integrins and other
CC       adhesion receptors, receptor protein tyrosine kinases, G protein-
CC       coupled receptors as well as cytokine receptors. Participates in
CC       signaling pathways that control a diverse spectrum of biological
CC       activities including gene transcription, immune response, cell
CC       adhesion, cell cycle progression, apoptosis, migration, and
CC       transformation. Due to functional redundancy between members of
CC       the SRC kinase family, identification of the specific role of each
CC       SRC kinase is very difficult. SRC appears to be one of the primary
CC       kinases activated following engagement of receptors and plays a
CC       role in the activation of other protein tyrosine kinase (PTK)
CC       families. Receptor clustering or dimerization leads to recruitment
CC       of SRC to the receptor complexes where it phosphorylates the
CC       tyrosine residues within the receptor cytoplasmic domains. Plays
CC       an important role in the regulation of cytoskeletal organization
CC       through phosphorylation of specific substrates such as AFAP1.
CC       Phosphorylation of AFAP1 allows the SRC SH2 domain to bind AFAP1
CC       and to localize to actin filaments. Cytoskeletal reorganization is
CC       also controlled through the phosphorylation of cortactin (CTTN).
CC       When cells adhere via focal adhesions to the extracellular matrix,
CC       signals are transmitted by integrins into the cell resulting in
CC       tyrosine phosphorylation of a number of focal adhesion proteins,
CC       including PTK2/FAK1 and paxillin (PXN). In addition to
CC       phosphorylating focal adhesion proteins, SRC is also active at the
CC       sites of cell-cell contact adherens junctions and phosphorylates
CC       substrates such as beta-catenin (CTNNB1), delta-catenin (CTNND1),
CC       and plakoglobin (JUP). Another type of cell-cell junction, the gap
CC       junction, is also a target for SRC, which phosphorylates connexin-
CC       43 (GJA1). SRC is implicated in regulation of pre-mRNA-processing
CC       and phosphorylates RNA-binding proteins such as KHDRBS1. Also
CC       plays a role in PDGF-mediated tyrosine phosphorylation of both
CC       STAT1 and STAT3, leading to increased DNA binding activity of
CC       these transcription factors. Involved in the RAS pathway through
CC       phosphorylation of RASA1 and RASGRF1. Plays a role in EGF-mediated
CC       calcium-activated chloride channel activation. Required for
CC       epidermal growth factor receptor (EGFR) internalization through
CC       phosphorylation of clathrin heavy chain (CLTC and CLTCL1) at 'Tyr-
CC       1477'. Involved in beta-arrestin (ARRB1 and ARRB2) desensitization
CC       through phosphorylation and activation of GRK2, leading to beta-
CC       arrestin phosphorylation and internalization. Has a critical role
CC       in the stimulation of the CDK20/MAPK3 mitogen-activated protein
CC       kinase cascade by epidermal growth factor. Might be involved not
CC       only in mediating the transduction of mitogenic signals at the
CC       level of the plasma membrane but also in controlling progression
CC       through the cell cycle via interaction with regulatory proteins in
CC       the nucleus. Plays an important role in osteoclastic bone
CC       resorption in conjunction with PTK2B/PYK2. Both the formation of a
CC       SRC-PTK2B/PYK2 complex and SRC kinase activity are necessary for
CC       this function. Recruited to activated integrins by PTK2B/PYK2,
CC       thereby phosphorylating CBL, which in turn induces the activation
CC       and recruitment of phosphatidylinositol 3-kinase to the cell
CC       membrane in a signaling pathway that is critical for osteoclast
CC       function. Promotes energy production in osteoclasts by activating
CC       mitochondrial cytochrome C oxidase. Phosphorylates DDR2 on
CC       tyrosine residues, thereby promoting its subsequent
CC       autophosphorylation. Phosphorylates RUNX3 and COX2 on tyrosine
CC       residues, TNK2 on 'Tyr-284' and CBL on 'Tyr-731'. Enhances
CC       DDX58/RIG-I-elicited antiviral signaling. Phosphorylates PDPK1 at
CC       'Tyr-9', 'Tyr-373' and 'Tyr-376'. Phosphorylates BCAR1 at 'Tyr-
CC       128'. Phosphorylates CBLC at multiple tyrosine residues,
CC       phosphorylation at 'Tyr-341' activates CBLC E3 activity. Required
CC       for podosome formation (By similarity).
CC       {ECO:0000250|UniProtKB:P05480, ECO:0000269|PubMed:11389730,
CC       ECO:0000269|PubMed:12615910, ECO:0000269|PubMed:14585963,
CC       ECO:0000269|PubMed:16186108, ECO:0000269|PubMed:18586953,
CC       ECO:0000269|PubMed:19419966, ECO:0000269|PubMed:20100835,
CC       ECO:0000269|PubMed:20525694, ECO:0000269|PubMed:21309750,
CC       ECO:0000269|PubMed:21411625, ECO:0000269|PubMed:22710723,
CC       ECO:0000269|PubMed:2498394, ECO:0000269|PubMed:3093483,
CC       ECO:0000269|PubMed:7853507, ECO:0000269|PubMed:8755529,
CC       ECO:0000269|PubMed:8759729}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: Phosphorylation by CSK at Tyr-530 inhibits
CC       kinase activity. Inhibitory phosphorylation at Tyr-530 is enhanced
CC       by heme. Further phosphorylation by CDK1 partially reactivates
CC       CSK-inactivated SRC and facilitates complete reactivation by
CC       protein tyrosine phosphatase PTPRC. Integrin engagement stimulates
CC       kinase activity. Phosphorylation by PTK2/FAK1 enhances kinase
CC       activity. Butein and pseudosubstrate-based peptide inhibitors like
CC       CIYKYYF act as inhibitors. Phosphorylation at Tyr-419 increases
CC       kinase activity. {ECO:0000269|PubMed:14632929,
CC       ECO:0000269|PubMed:21036157, ECO:0000269|PubMed:7929427,
CC       ECO:0000269|PubMed:8759729, ECO:0000269|PubMed:9571170}.
CC   -!- SUBUNIT: Interacts with DDEF1/ASAP1; via the SH3 domain. Interacts
CC       with CCPG1. Identified in a complex containing FGFR4, NCAM1, CDH2,
CC       PLCG1, FRS2, SRC, SHC1, GAP43 and CTTN. Interacts with ERBB2,
CC       STAT1 and PNN. Interacts with DDR1, DDR2 and DAB2. Interacts with
CC       CDCP1, PELP1, TGFB1I1 and TOM1L2. Interacts with the cytoplasmic
CC       domain of MUC1, phosphorylates it and increases binding of MUC1
CC       with beta-catenin. Interacts with RALGPS1; via the SH3 domain.
CC       Interacts with HEV ORF3 protein; via the SH3 domain. Interacts
CC       with CAV2 (tyrosine phosphorylated form). Interacts (via the SH3
CC       domain and the protein kinase domain) with ARRB1; the interaction
CC       is independent of the phosphorylation state of SRC C-terminus.
CC       Interacts with ARRB1 and ARRB2. Interacts with SRCIN1. Interacts
CC       with NDFIP2 and more weakly with NDFIP1. Interacts with PIK3CA
CC       and/or PIK3C2B, PTK2/FAK1 and ESR1 (dimethylated on arginine).
CC       Interacts with FASLG. Interacts (via SH2 domain) with the 'Tyr-
CC       402' phosphorylated form of PTK2B/PYK2. Interacts (via SH2 domain)
CC       with FLT3 (tyrosine phosphorylated). Interacts with PDGFRA
CC       (tyrosine phosphorylated). Interacts with CSF1R. Interacts (via
CC       SH2 and SH3 domain) with TNK2. Interacts (via protein kinase
CC       domain) with the tyrosine phosphorylated form of RUNX3 (via runt
CC       domain). Interacts with TRAF3 (via RING-type zinc finger domain).
CC       Interacts with DDX58, MAVS and TBK1. Interacts (via SH2 domain)
CC       with RACK1; the interaction is enhanced by tyrosine
CC       phosphorylation of RACK1 and inhibits SRC activity. Interacts with
CC       EPHB1; activates the MAPK/ERK cascade to regulate cell migration.
CC       Interacts with FCAMR. Interacts (via SH2 domain) with the 'Tyr-9'
CC       phosphorylated form of PDPK1. Interacts with AMOTL2; this
CC       interaction regulates the translocation of phosphorylated SRC to
CC       peripheral cell-matrix adhesion sites. Interacts with TRAP1.
CC       Interacts with CBLC; the interaction is enhanced when SRC is
CC       phosphorylated at Tyr-419. Interacts with ARHGEF5 (By similarity).
CC       Interacts (via cytoplasmic domain) with CEACAM1 (via SH2 domain);
CC       this interaction is regulated by trans-homophilic cell adhesion
CC       (By similarity) (PubMed:7478590). Interacts with MPP2
CC       (PubMed:19665017). {ECO:0000250|UniProtKB:P05480,
CC       ECO:0000250|UniProtKB:Q9WUD9, ECO:0000269|PubMed:10747847,
CC       ECO:0000269|PubMed:10753943, ECO:0000269|PubMed:11152665,
CC       ECO:0000269|PubMed:11279199, ECO:0000269|PubMed:11518702,
CC       ECO:0000269|PubMed:12091389, ECO:0000269|PubMed:12415108,
CC       ECO:0000269|PubMed:12925710, ECO:0000269|PubMed:14585963,
CC       ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:15504032,
CC       ECO:0000269|PubMed:15851033, ECO:0000269|PubMed:16479011,
CC       ECO:0000269|PubMed:17202804, ECO:0000269|PubMed:17293535,
CC       ECO:0000269|PubMed:17525734, ECO:0000269|PubMed:18024423,
CC       ECO:0000269|PubMed:18657504, ECO:0000269|PubMed:19419966,
CC       ECO:0000269|PubMed:19665017, ECO:0000269|PubMed:19807924,
CC       ECO:0000269|PubMed:20100835, ECO:0000269|PubMed:20534535,
CC       ECO:0000269|PubMed:21309750, ECO:0000269|PubMed:21411625,
CC       ECO:0000269|PubMed:22888118, ECO:0000269|PubMed:23564345,
CC       ECO:0000269|PubMed:7478590, ECO:0000269|PubMed:8759729,
CC       ECO:0000269|PubMed:9584165, ECO:0000269|PubMed:9924018}.
CC   -!- INTERACTION:
CC       P00519:ABL1; NbExp=2; IntAct=EBI-621482, EBI-375543;
CC       P42684:ABL2; NbExp=2; IntAct=EBI-621482, EBI-1102694;
CC       P12814:ACTN1; NbExp=2; IntAct=EBI-621482, EBI-351710;
CC       Q13444:ADAM15; NbExp=3; IntAct=EBI-621482, EBI-77818;
CC       P07550:ADRB2; NbExp=3; IntAct=EBI-621482, EBI-491169;
CC       P55196:AFDN; NbExp=7; IntAct=EBI-621482, EBI-365875;
CC       P10275:AR; NbExp=7; IntAct=EBI-621482, EBI-608057;
CC       Q8R5G7:Arap3 (xeno); NbExp=3; IntAct=EBI-621482, EBI-621463;
CC       Q9ULH1:ASAP1; NbExp=3; IntAct=EBI-621482, EBI-346622;
CC       P56945:BCAR1; NbExp=3; IntAct=EBI-621482, EBI-702093;
CC       P22681:CBL; NbExp=8; IntAct=EBI-621482, EBI-518228;
CC       P12830:CDH1; NbExp=2; IntAct=EBI-621482, EBI-727477;
CC       P52800:Efnb2 (xeno); NbExp=2; IntAct=EBI-621482, EBI-1032676;
CC       P00533:EGFR; NbExp=7; IntAct=EBI-621482, EBI-297353;
CC       P04626:ERBB2; NbExp=11; IntAct=EBI-621482, EBI-641062;
CC       P21860:ERBB3; NbExp=2; IntAct=EBI-621482, EBI-720706;
CC       P03372:ESR1; NbExp=9; IntAct=EBI-621482, EBI-78473;
CC       P03372-4:ESR1; NbExp=2; IntAct=EBI-621482, EBI-4309277;
CC       P14921-1:ETS1; NbExp=2; IntAct=EBI-621482, EBI-913224;
CC       P25445:FAS; NbExp=2; IntAct=EBI-621482, EBI-494743;
CC       Q8NFZ0:FBXO18; NbExp=4; IntAct=EBI-621482, EBI-724767;
CC       Q13480:GAB1; NbExp=12; IntAct=EBI-621482, EBI-517684;
CC       P61978:HNRNPK; NbExp=6; IntAct=EBI-621482, EBI-304185;
CC       P97288:Htr4 (xeno); NbExp=2; IntAct=EBI-621482, EBI-7149283;
CC       Q9Y6K9:IKBKG; NbExp=3; IntAct=EBI-621482, EBI-81279;
CC       P35968:KDR; NbExp=2; IntAct=EBI-621482, EBI-1005487;
CC       Q07666:KHDRBS1; NbExp=3; IntAct=EBI-621482, EBI-1364;
CC       P10721:KIT; NbExp=5; IntAct=EBI-621482, EBI-1379503;
CC       Q8TBB1:LNX1; NbExp=6; IntAct=EBI-621482, EBI-739832;
CC       P07948:LYN; NbExp=2; IntAct=EBI-621482, EBI-79452;
CC       Q9H204:MED28; NbExp=3; IntAct=EBI-621482, EBI-514199;
CC       P08581:MET; NbExp=4; IntAct=EBI-621482, EBI-1039152;
CC       Q13177:PAK2; NbExp=2; IntAct=EBI-621482, EBI-1045887;
CC       P16284:PECAM1; NbExp=3; IntAct=EBI-621482, EBI-716404;
CC       P27986:PIK3R1; NbExp=6; IntAct=EBI-621482, EBI-79464;
CC       Q92569:PIK3R3; NbExp=3; IntAct=EBI-621482, EBI-79893;
CC       Q05397:PTK2; NbExp=8; IntAct=EBI-621482, EBI-702142;
CC       P34152:Ptk2 (xeno); NbExp=2; IntAct=EBI-621482, EBI-77070;
CC       Q14289:PTK2B; NbExp=3; IntAct=EBI-621482, EBI-298640;
CC       P18031:PTPN1; NbExp=14; IntAct=EBI-621482, EBI-968788;
CC       Q16825:PTPN21; NbExp=2; IntAct=EBI-621482, EBI-2860264;
CC       P18433:PTPRA; NbExp=4; IntAct=EBI-621482, EBI-2609645;
CC       P18052:Ptpra (xeno); NbExp=3; IntAct=EBI-621482, EBI-6597520;
CC       Q62884:Ptprj (xeno); NbExp=3; IntAct=EBI-621482, EBI-7459400;
CC       Q13905:RAPGEF1; NbExp=2; IntAct=EBI-621482, EBI-976876;
CC       Q01973:ROR1; NbExp=9; IntAct=EBI-621482, EBI-6082337;
CC       P27635:RPL10; NbExp=6; IntAct=EBI-621482, EBI-352398;
CC       P35326:SPRR2A; NbExp=3; IntAct=EBI-621482, EBI-1047940;
CC       Q9C0H9:SRCIN1; NbExp=3; IntAct=EBI-621482, EBI-1393949;
CC       Q68CZ2:TNS3; NbExp=13; IntAct=EBI-621482, EBI-1220488;
CC   -!- SUBCELLULAR LOCATION: Cell membrane. Mitochondrion inner membrane.
CC       Nucleus. Cytoplasm, cytoskeleton. Note=Localizes to focal adhesion
CC       sites following integrin engagement. Localization to focal
CC       adhesion sites requires myristoylation and the SH3 domain.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P12931-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P12931-2; Sequence=VSP_012134;
CC   -!- TISSUE SPECIFICITY: Expressed ubiquitously. Platelets, neurons and
CC       osteoclasts express 5-fold to 200-fold higher levels than most
CC       other tissues.
CC   -!- DOMAIN: The SH2 and SH3 domains are important for the
CC       intramolecular and intermolecular interactions that regulate
CC       catalytic activity, localization, and substrate recruitment.
CC   -!- PTM: Myristoylated at Gly-2, and this is essential for targeting
CC       to membranes. {ECO:0000269|PubMed:7525268}.
CC   -!- PTM: Dephosphorylated at Tyr-530 by PTPRJ (By similarity).
CC       Phosphorylated on Tyr-530 by c-Src kinase (CSK). The
CC       phosphorylated form is termed pp60c-src. Dephosphorylated by PTPRJ
CC       at Tyr-419. Normally maintained in an inactive conformation with
CC       the SH2 domain engaged with Tyr-530, the SH3 domain engaged with
CC       the SH2-kinase linker, and Tyr-419 dephosphorylated.
CC       Dephosphorylation of Tyr-530 as a result of protein tyrosine
CC       phosphatase (PTP) action disrupts the intramolecular interaction
CC       between the SH2 domain and Tyr-530, Tyr-419 can then become
CC       autophosphorylated, resulting in SRC activation. Phosphorylation
CC       of Tyr-530 by CSK allows this interaction to reform, resulting in
CC       SRC inactivation. CDK5-mediated phosphorylation at Ser-75 targets
CC       SRC to ubiquitin-dependent degradation and thus leads to
CC       cytoskeletal reorganization. Phosphorylated by PTK2/FAK1; this
CC       enhances kinase activity. Phosphorylated by PTK2B/PYK2; this
CC       enhances kinase activity. {ECO:0000250,
CC       ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:18936167,
CC       ECO:0000269|PubMed:21442427, ECO:0000269|PubMed:22888118,
CC       ECO:0000269|PubMed:6273838, ECO:0000269|PubMed:7525268}.
CC   -!- PTM: S-nitrosylation is important for activation of its kinase
CC       activity. {ECO:0000250}.
CC   -!- PTM: Ubiquitinated in response to CDK5-mediated phosphorylation.
CC       Ubiquitination mediated by CBLC requires SRC autophosphorylation
CC       at Tyr-419 and may lead to lysosomal degradation.
CC       {ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:18936167,
CC       ECO:0000269|PubMed:22888118, ECO:0000269|PubMed:6273838}.
CC   -!- DISEASE: Note=SRC kinase activity has been shown to be increased
CC       in several tumor tissues and tumor cell lines such as colon
CC       carcinoma cells.
CC   -!- DISEASE: Thrombocytopenia 6 (THC6) [MIM:616937]: A form of
CC       thrombocytopenia, a hematologic disorder defined by a decrease in
CC       the number of platelets in circulating blood, resulting in the
CC       potential for increased bleeding and decreased ability for
CC       clotting. THC6 is an autosomal dominant form. Affected individuals
CC       may also have bone abnormalities and an increased risk for
CC       myelofibrosis. {ECO:0000269|PubMed:26936507}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. SRC subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/SRCID448ch20q11.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL133293; CAC10573.1; -; Genomic_DNA.
DR   EMBL; AL133293; CAC34523.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW76065.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW76064.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW76066.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW76067.1; -; Genomic_DNA.
DR   EMBL; BC011566; AAH11566.1; -; mRNA.
DR   EMBL; BC051270; AAH51270.2; -; mRNA.
DR   EMBL; K03218; AAA60584.1; -; Genomic_DNA.
DR   EMBL; M16237; AAA60584.1; JOINED; Genomic_DNA.
DR   EMBL; M16243; AAA60584.1; JOINED; Genomic_DNA.
DR   EMBL; M16244; AAA60584.1; JOINED; Genomic_DNA.
DR   EMBL; M16245; AAA60584.1; JOINED; Genomic_DNA.
DR   EMBL; K03212; AAA60584.1; JOINED; Genomic_DNA.
DR   EMBL; K03213; AAA60584.1; JOINED; Genomic_DNA.
DR   EMBL; K03214; AAA60584.1; JOINED; Genomic_DNA.
DR   EMBL; K03215; AAA60584.1; JOINED; Genomic_DNA.
DR   EMBL; K03216; AAA60584.1; JOINED; Genomic_DNA.
DR   EMBL; K03217; AAA60584.1; JOINED; Genomic_DNA.
DR   EMBL; X02647; CAA26485.1; -; Genomic_DNA.
DR   EMBL; X03995; CAA26485.1; JOINED; Genomic_DNA.
DR   EMBL; X03996; CAA26485.1; JOINED; Genomic_DNA.
DR   EMBL; X03997; CAA26485.1; JOINED; Genomic_DNA.
DR   EMBL; X03998; CAA26485.1; JOINED; Genomic_DNA.
DR   EMBL; X03999; CAA26485.1; JOINED; Genomic_DNA.
DR   EMBL; X04000; CAA26485.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS13294.1; -. [P12931-1]
DR   PIR; A26891; TVHUSC.
DR   RefSeq; NP_005408.1; NM_005417.4. [P12931-1]
DR   RefSeq; NP_938033.1; NM_198291.2. [P12931-1]
DR   RefSeq; XP_011527315.1; XM_011529013.2. [P12931-1]
DR   RefSeq; XP_016883513.1; XM_017028024.1. [P12931-2]
DR   RefSeq; XP_016883514.1; XM_017028025.1. [P12931-2]
DR   RefSeq; XP_016883515.1; XM_017028026.1. [P12931-2]
DR   RefSeq; XP_016883516.1; XM_017028027.1. [P12931-2]
DR   UniGene; Hs.195659; -.
DR   PDB; 1A07; X-ray; 2.20 A; A/B=144-249.
DR   PDB; 1A08; X-ray; 2.20 A; A/B=144-249.
DR   PDB; 1A09; X-ray; 2.00 A; A/B=144-249.
DR   PDB; 1A1A; X-ray; 2.00 A; A/B=144-249.
DR   PDB; 1A1B; X-ray; 2.20 A; A/B=144-249.
DR   PDB; 1A1C; X-ray; 2.40 A; A/B=144-249.
DR   PDB; 1A1E; X-ray; 2.20 A; A/B=144-249.
DR   PDB; 1FMK; X-ray; 1.50 A; A=86-536.
DR   PDB; 1HCS; NMR; -; B=144-249.
DR   PDB; 1HCT; NMR; -; B=144-249.
DR   PDB; 1KSW; X-ray; 2.80 A; A=86-536.
DR   PDB; 1O41; X-ray; 1.70 A; A=145-252.
DR   PDB; 1O42; X-ray; 1.70 A; A=145-252.
DR   PDB; 1O43; X-ray; 1.50 A; A=145-252.
DR   PDB; 1O44; X-ray; 1.70 A; A=145-252.
DR   PDB; 1O45; X-ray; 1.80 A; A=145-252.
DR   PDB; 1O46; X-ray; 2.00 A; A=145-252.
DR   PDB; 1O47; X-ray; 1.80 A; A=145-252.
DR   PDB; 1O48; X-ray; 1.55 A; A=145-252.
DR   PDB; 1O49; X-ray; 1.70 A; A=145-252.
DR   PDB; 1O4A; X-ray; 1.50 A; A=145-252.
DR   PDB; 1O4B; X-ray; 1.85 A; A=145-252.
DR   PDB; 1O4C; X-ray; 1.80 A; A=145-252.
DR   PDB; 1O4D; X-ray; 1.85 A; A=145-252.
DR   PDB; 1O4E; X-ray; 2.00 A; A=145-252.
DR   PDB; 1O4F; X-ray; 2.00 A; A=145-252.
DR   PDB; 1O4G; X-ray; 1.55 A; A=145-252.
DR   PDB; 1O4H; X-ray; 2.25 A; A=145-252.
DR   PDB; 1O4I; X-ray; 1.75 A; A=145-252.
DR   PDB; 1O4J; X-ray; 1.70 A; A=145-252.
DR   PDB; 1O4K; X-ray; 1.57 A; A=145-252.
DR   PDB; 1O4L; X-ray; 1.65 A; A=145-252.
DR   PDB; 1O4M; X-ray; 1.60 A; A=145-252.
DR   PDB; 1O4N; X-ray; 1.60 A; A=145-252.
DR   PDB; 1O4O; X-ray; 1.70 A; A=145-252.
DR   PDB; 1O4P; X-ray; 1.90 A; A=145-252.
DR   PDB; 1O4Q; X-ray; 1.70 A; A=145-252.
DR   PDB; 1O4R; X-ray; 1.50 A; A=145-252.
DR   PDB; 1SHD; X-ray; 2.00 A; A=144-249.
DR   PDB; 1Y57; X-ray; 1.91 A; A=86-536.
DR   PDB; 1YI6; X-ray; 2.00 A; A/B=261-536.
DR   PDB; 1YOJ; X-ray; 1.95 A; A/B=254-536.
DR   PDB; 1YOL; X-ray; 2.30 A; A/B=254-536.
DR   PDB; 1YOM; X-ray; 2.90 A; A/B=254-536.
DR   PDB; 2BDF; X-ray; 2.10 A; A/B=258-536.
DR   PDB; 2BDJ; X-ray; 2.50 A; A=258-536.
DR   PDB; 2H8H; X-ray; 2.20 A; A=2-536.
DR   PDB; 2SRC; X-ray; 1.50 A; A=86-536.
DR   PDB; 3VRO; X-ray; 1.80 A; B=412-424.
DR   PDB; 3ZMP; X-ray; 2.62 A; C/D=527-536.
DR   PDB; 3ZMQ; X-ray; 3.30 A; C=527-536.
DR   PDB; 4F59; X-ray; 1.71 A; A=144-252.
DR   PDB; 4F5A; X-ray; 1.80 A; A=144-252.
DR   PDB; 4F5B; X-ray; 1.57 A; A=144-252.
DR   PDB; 4HXJ; X-ray; 2.00 A; A/B=87-144.
DR   PDB; 4K11; X-ray; 2.30 A; A=87-534.
DR   PDB; 4MXO; X-ray; 2.10 A; A/B=254-536.
DR   PDB; 4MXX; X-ray; 2.60 A; A/B=254-536.
DR   PDB; 4MXY; X-ray; 2.58 A; A/B=254-536.
DR   PDB; 4MXZ; X-ray; 2.58 A; A/B=254-536.
DR   PDBsum; 1A07; -.
DR   PDBsum; 1A08; -.
DR   PDBsum; 1A09; -.
DR   PDBsum; 1A1A; -.
DR   PDBsum; 1A1B; -.
DR   PDBsum; 1A1C; -.
DR   PDBsum; 1A1E; -.
DR   PDBsum; 1FMK; -.
DR   PDBsum; 1HCS; -.
DR   PDBsum; 1HCT; -.
DR   PDBsum; 1KSW; -.
DR   PDBsum; 1O41; -.
DR   PDBsum; 1O42; -.
DR   PDBsum; 1O43; -.
DR   PDBsum; 1O44; -.
DR   PDBsum; 1O45; -.
DR   PDBsum; 1O46; -.
DR   PDBsum; 1O47; -.
DR   PDBsum; 1O48; -.
DR   PDBsum; 1O49; -.
DR   PDBsum; 1O4A; -.
DR   PDBsum; 1O4B; -.
DR   PDBsum; 1O4C; -.
DR   PDBsum; 1O4D; -.
DR   PDBsum; 1O4E; -.
DR   PDBsum; 1O4F; -.
DR   PDBsum; 1O4G; -.
DR   PDBsum; 1O4H; -.
DR   PDBsum; 1O4I; -.
DR   PDBsum; 1O4J; -.
DR   PDBsum; 1O4K; -.
DR   PDBsum; 1O4L; -.
DR   PDBsum; 1O4M; -.
DR   PDBsum; 1O4N; -.
DR   PDBsum; 1O4O; -.
DR   PDBsum; 1O4P; -.
DR   PDBsum; 1O4Q; -.
DR   PDBsum; 1O4R; -.
DR   PDBsum; 1SHD; -.
DR   PDBsum; 1Y57; -.
DR   PDBsum; 1YI6; -.
DR   PDBsum; 1YOJ; -.
DR   PDBsum; 1YOL; -.
DR   PDBsum; 1YOM; -.
DR   PDBsum; 2BDF; -.
DR   PDBsum; 2BDJ; -.
DR   PDBsum; 2H8H; -.
DR   PDBsum; 2SRC; -.
DR   PDBsum; 3VRO; -.
DR   PDBsum; 3ZMP; -.
DR   PDBsum; 3ZMQ; -.
DR   PDBsum; 4F59; -.
DR   PDBsum; 4F5A; -.
DR   PDBsum; 4F5B; -.
DR   PDBsum; 4HXJ; -.
DR   PDBsum; 4K11; -.
DR   PDBsum; 4MXO; -.
DR   PDBsum; 4MXX; -.
DR   PDBsum; 4MXY; -.
DR   PDBsum; 4MXZ; -.
DR   ProteinModelPortal; P12931; -.
DR   SMR; P12931; -.
DR   BioGrid; 112592; 263.
DR   DIP; DIP-1059N; -.
DR   IntAct; P12931; 191.
DR   MINT; MINT-93621; -.
DR   STRING; 9606.ENSP00000350941; -.
DR   BindingDB; P12931; -.
DR   ChEMBL; CHEMBL267; -.
DR   DrugBank; DB08564; (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide.
DR   DrugBank; DB06882; 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea.
DR   DrugBank; DB06883; 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea.
DR   DrugBank; DB08192; 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE.
DR   DrugBank; DB04739; 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE.
DR   DrugBank; DB07966; [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile.
DR   DrugBank; DB06616; Bosutinib.
DR   DrugBank; DB04272; Citric Acid.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB03217; DPI59.
DR   DrugBank; DB03628; ISO24.
DR   DrugBank; DB02175; Malonic acid.
DR   DrugBank; DB08462; N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE.
DR   DrugBank; DB07662; N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE.
DR   DrugBank; DB01893; N6-Benzyl Adenosine-5'-Diphosphate.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB03902; Oxalic Acid.
DR   DrugBank; DB03114; PAS219.
DR   DrugBank; DB03078; PASBN.
DR   DrugBank; DB03298; Phenylphosphate.
DR   DrugBank; DB01962; Phosphonotyrosine.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB04751; Purvalanol A.
DR   DrugBank; DB04080; RU78191.
DR   DrugBank; DB01947; RU78262.
DR   DrugBank; DB03828; RU78299.
DR   DrugBank; DB03306; RU78300.
DR   DrugBank; DB02908; RU78783.
DR   DrugBank; DB02762; RU79072.
DR   DrugBank; DB03525; RU79073.
DR   DrugBank; DB01866; RU79256.
DR   DrugBank; DB04495; RU81843.
DR   DrugBank; DB03104; RU82129.
DR   DrugBank; DB03268; RU82197.
DR   DrugBank; DB03591; RU82209.
DR   DrugBank; DB02336; RU83876.
DR   DrugBank; DB01678; RU84687.
DR   DrugBank; DB03712; RU85053.
DR   DrugBank; DB01908; RU85493.
DR   DrugBank; DB02432; RU90395.
DR   DrugBank; DB05184; XL228.
DR   GuidetoPHARMACOLOGY; 2206; -.
DR   iPTMnet; P12931; -.
DR   PhosphoSitePlus; P12931; -.
DR   SwissPalm; P12931; -.
DR   DMDM; 125711; -.
DR   OGP; P12931; -.
DR   EPD; P12931; -.
DR   MaxQB; P12931; -.
DR   PaxDb; P12931; -.
DR   PeptideAtlas; P12931; -.
DR   PRIDE; P12931; -.
DR   DNASU; 6714; -.
DR   Ensembl; ENST00000358208; ENSP00000350941; ENSG00000197122. [P12931-1]
DR   Ensembl; ENST00000373558; ENSP00000362659; ENSG00000197122. [P12931-2]
DR   Ensembl; ENST00000373567; ENSP00000362668; ENSG00000197122. [P12931-1]
DR   Ensembl; ENST00000373578; ENSP00000362680; ENSG00000197122. [P12931-1]
DR   GeneID; 6714; -.
DR   KEGG; hsa:6714; -.
DR   UCSC; uc002xgy.5; human. [P12931-1]
DR   CTD; 6714; -.
DR   DisGeNET; 6714; -.
DR   GeneCards; SRC; -.
DR   HGNC; HGNC:11283; SRC.
DR   HPA; CAB004023; -.
DR   HPA; HPA030875; -.
DR   MalaCards; SRC; -.
DR   MIM; 190090; gene.
DR   MIM; 616937; phenotype.
DR   neXtProt; NX_P12931; -.
DR   OpenTargets; ENSG00000197122; -.
DR   PharmGKB; PA36111; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118938; -.
DR   HOGENOM; HOG000233858; -.
DR   HOVERGEN; HBG008761; -.
DR   InParanoid; P12931; -.
DR   KO; K05704; -.
DR   OMA; CQCWRKD; -.
DR   OrthoDB; EOG091G0D46; -.
DR   PhylomeDB; P12931; -.
DR   TreeFam; TF351634; -.
DR   BioCyc; MetaCyc:HS02256-MONOMER; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-1227986; Signaling by ERBB2.
DR   Reactome; R-HSA-1295596; Spry regulation of FGF signaling.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-1433559; Regulation of KIT signaling.
DR   Reactome; R-HSA-171007; p38MAPK events.
DR   Reactome; R-HSA-177929; Signaling by EGFR.
DR   Reactome; R-HSA-180292; GAB1 signalosome.
DR   Reactome; R-HSA-186763; Downstream signal transduction.
DR   Reactome; R-HSA-191647; c-src mediated regulation of Cx43 function and closure of gap junctions.
DR   Reactome; R-HSA-2029481; FCGR activation.
DR   Reactome; R-HSA-210990; PECAM1 interactions.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-354192; Integrin alphaIIb beta3 signaling.
DR   Reactome; R-HSA-354194; GRB2:SOS provides linkage to MAPK signaling for Integrins.
DR   Reactome; R-HSA-372708; p130Cas linkage to MAPK signaling for integrins.
DR   Reactome; R-HSA-375165; NCAM signaling for neurite out-growth.
DR   Reactome; R-HSA-389356; CD28 co-stimulation.
DR   Reactome; R-HSA-389513; CTLA4 inhibitory signaling.
DR   Reactome; R-HSA-391160; Signal regulatory protein (SIRP) family interactions.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-3928664; Ephrin signaling.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   Reactome; R-HSA-418592; ADP signalling through P2Y purinoceptor 1.
DR   Reactome; R-HSA-418885; DCC mediated attractive signaling.
DR   Reactome; R-HSA-418886; Netrin mediated repulsion signals.
DR   Reactome; R-HSA-430116; GP1b-IX-V activation signalling.
DR   Reactome; R-HSA-437239; Recycling pathway of L1.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-456926; Thrombin signalling through proteinase activated receptors (PARs).
DR   Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation.
DR   Reactome; R-HSA-5607764; CLEC7A (Dectin-1) signaling.
DR   Reactome; R-HSA-5663220; RHO GTPases Activate Formins.
DR   Reactome; R-HSA-5673000; RAF activation.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802949; Signaling by RAS mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF fusions.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8853659; RET signaling.
DR   Reactome; R-HSA-8874081; MET activates PTK2 signaling.
DR   Reactome; R-HSA-8876493; InlA-mediated entry of Listeria monocytogenes into host cells.
DR   SignaLink; P12931; -.
DR   SIGNOR; P12931; -.
DR   ChiTaRS; SRC; human.
DR   EvolutionaryTrace; P12931; -.
DR   GeneWiki; Src_(gene); -.
DR   GenomeRNAi; 6714; -.
DR   PMAP-CutDB; P12931; -.
DR   PRO; PR:P12931; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; ENSG00000197122; -.
DR   CleanEx; HS_SRC; -.
DR   Genevisible; P12931; HS.
DR   GO; GO:0005884; C:actin filament; IEA:Ensembl.
DR   GO; GO:0005901; C:caveola; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005770; C:late endosome; IDA:UniProtKB.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0002102; C:podosome; IEA:Ensembl.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0032587; C:ruffle membrane; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0045296; F:cadherin binding; IDA:BHF-UCL.
DR   GO; GO:0071253; F:connexin binding; IEA:Ensembl.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0046875; F:ephrin receptor binding; IPI:UniProtKB.
DR   GO; GO:0030331; F:estrogen receptor binding; IEA:Ensembl.
DR   GO; GO:0070851; F:growth factor receptor binding; IPI:UniProtKB.
DR   GO; GO:0020037; F:heme binding; IDA:UniProtKB.
DR   GO; GO:0051427; F:hormone receptor binding; IBA:GO_Central.
DR   GO; GO:0005158; F:insulin receptor binding; IEA:Ensembl.
DR   GO; GO:0005178; F:integrin binding; TAS:BHF-UCL.
DR   GO; GO:0044325; F:ion channel binding; IPI:BHF-UCL.
DR   GO; GO:0016301; F:kinase activity; TAS:Reactome.
DR   GO; GO:0019900; F:kinase binding; IPI:UniProtKB.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; TAS:BHF-UCL.
DR   GO; GO:0051219; F:phosphoprotein binding; IPI:UniProtKB.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:CAFA.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0005080; F:protein kinase C binding; IEA:Ensembl.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IPI:UniProtKB.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:BHF-UCL.
DR   GO; GO:0042169; F:SH2 domain binding; IPI:UniProtKB.
DR   GO; GO:0005070; F:SH3/SH2 adaptor activity; TAS:ProtInc.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IEA:Ensembl.
DR   GO; GO:0032148; P:activation of protein kinase B activity; IEA:Ensembl.
DR   GO; GO:0034332; P:adherens junction organization; IEA:Ensembl.
DR   GO; GO:0086098; P:angiotensin-activated signaling pathway involved in heart process; ISS:BHF-UCL.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0045453; P:bone resorption; ISS:UniProtKB.
DR   GO; GO:0060444; P:branching involved in mammary gland duct morphogenesis; IEA:Ensembl.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0008283; P:cell proliferation; IEA:Ensembl.
DR   GO; GO:0071398; P:cellular response to fatty acid; IEA:Ensembl.
DR   GO; GO:0071498; P:cellular response to fluid shear stress; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IEA:Ensembl.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0071375; P:cellular response to peptide hormone stimulus; ISS:BHF-UCL.
DR   GO; GO:0036120; P:cellular response to platelet-derived growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071393; P:cellular response to progesterone stimulus; ISS:BHF-UCL.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; IEA:Ensembl.
DR   GO; GO:0007417; P:central nervous system development; IBA:GO_Central.
DR   GO; GO:0035635; P:entry of bacterium into host cell; TAS:Reactome.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0038128; P:ERBB2 signaling pathway; TAS:Reactome.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0030900; P:forebrain development; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0030520; P:intracellular estrogen receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:BHF-UCL.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:2000811; P:negative regulation of anoikis; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0051895; P:negative regulation of focal adhesion assembly; ISS:BHF-UCL.
DR   GO; GO:2001243; P:negative regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0051902; P:negative regulation of mitochondrial depolarization; IMP:UniProtKB.
DR   GO; GO:0032463; P:negative regulation of protein homooligomerization; IMP:UniProtKB.
DR   GO; GO:0051974; P:negative regulation of telomerase activity; IMP:BHF-UCL.
DR   GO; GO:0032211; P:negative regulation of telomere maintenance via telomerase; IMP:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0048477; P:oogenesis; IEA:Ensembl.
DR   GO; GO:0036035; P:osteoclast development; IBA:GO_Central.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:MGI.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0045737; P:positive regulation of cyclin-dependent protein serine/threonine kinase activity; IEA:Ensembl.
DR   GO; GO:0050715; P:positive regulation of cytokine secretion; IEA:Ensembl.
DR   GO; GO:2000573; P:positive regulation of DNA biosynthetic process; IEA:Ensembl.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0010907; P:positive regulation of glucose metabolic process; IEA:Ensembl.
DR   GO; GO:0046628; P:positive regulation of insulin receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0033625; P:positive regulation of integrin activation; TAS:BHF-UCL.
DR   GO; GO:2000394; P:positive regulation of lamellipodium morphogenesis; IMP:UniProtKB.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IEA:Ensembl.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IC:UniProtKB.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IEA:Ensembl.
DR   GO; GO:0010641; P:positive regulation of platelet-derived growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0071803; P:positive regulation of podosome assembly; IEA:Ensembl.
DR   GO; GO:0031954; P:positive regulation of protein autophosphorylation; IEA:Ensembl.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:1900182; P:positive regulation of protein localization to nucleus; IEA:Ensembl.
DR   GO; GO:0010954; P:positive regulation of protein processing; IEA:Ensembl.
DR   GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0051057; P:positive regulation of small GTPase mediated signal transduction; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0014911; P:positive regulation of smooth muscle cell migration; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0050847; P:progesterone receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0031648; P:protein destabilization; IEA:Ensembl.
DR   GO; GO:0045124; P:regulation of bone resorption; TAS:BHF-UCL.
DR   GO; GO:2001286; P:regulation of caveolin-mediated endocytosis; IMP:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; IBA:GO_Central.
DR   GO; GO:0060491; P:regulation of cell projection assembly; IEA:Ensembl.
DR   GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
DR   GO; GO:0022407; P:regulation of cell-cell adhesion; IMP:UniProtKB.
DR   GO; GO:2000641; P:regulation of early endosome to late endosome transport; IMP:UniProtKB.
DR   GO; GO:0010632; P:regulation of epithelial cell migration; IMP:UniProtKB.
DR   GO; GO:0033146; P:regulation of intracellular estrogen receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0071801; P:regulation of podosome assembly; IBA:GO_Central.
DR   GO; GO:0043393; P:regulation of protein binding; IEA:Ensembl.
DR   GO; GO:0043114; P:regulation of vascular permeability; TAS:BHF-UCL.
DR   GO; GO:0010447; P:response to acidic pH; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0051602; P:response to electrical stimulus; IEA:Ensembl.
DR   GO; GO:0042542; P:response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0070555; P:response to interleukin-1; IMP:BHF-UCL.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0051385; P:response to mineralocorticoid; IEA:Ensembl.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   GO; GO:0009615; P:response to virus; IEA:Ensembl.
DR   GO; GO:0007172; P:signal complex assembly; TAS:ProtInc.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0016337; P:single organismal cell-cell adhesion; IEA:Ensembl.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0043149; P:stress fiber assembly; IMP:UniProtKB.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IEA:Ensembl.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0045056; P:transcytosis; IEA:Ensembl.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0060065; P:uterus development; IEA:Ensembl.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell adhesion;
KW   Cell cycle; Cell membrane; Complete proteome; Cytoplasm; Cytoskeleton;
KW   Disease mutation; Host-virus interaction; Immunity; Kinase;
KW   Lipoprotein; Membrane; Mitochondrion; Mitochondrion inner membrane;
KW   Myristate; Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Proto-oncogene; Reference proteome; SH2 domain; SH3 domain;
KW   Transferase; Tyrosine-protein kinase; Ubl conjugation.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    536       Proto-oncogene tyrosine-protein kinase
FT                                Src.
FT                                /FTId=PRO_0000088141.
FT   DOMAIN       84    145       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN      151    248       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      270    523       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     276    284       ATP.
FT   ACT_SITE    389    389       Proton acceptor.
FT   BINDING     298    298       ATP.
FT   MOD_RES      17     17       Phosphoserine.
FT                                {ECO:0000244|PubMed:18088087,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES      35     35       Phosphoserine.
FT                                {ECO:0000269|PubMed:7929427}.
FT   MOD_RES      69     69       Phosphoserine.
FT                                {ECO:0000269|PubMed:7929427}.
FT   MOD_RES      74     74       Phosphothreonine.
FT                                {ECO:0000269|PubMed:7929427}.
FT   MOD_RES      75     75       Phosphoserine; by CDK5.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:21442427}.
FT   MOD_RES     187    187       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P05480}.
FT   MOD_RES     419    419       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14661060,
FT                                ECO:0000269|PubMed:18936167,
FT                                ECO:0000269|PubMed:26936507,
FT                                ECO:0000269|PubMed:6273838}.
FT   MOD_RES     419    419       Phosphotyrosine; by FAK2. {ECO:0000250}.
FT   MOD_RES     439    439       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:7929427}.
FT   MOD_RES     511    511       Phosphothreonine.
FT                                {ECO:0000269|PubMed:7929427}.
FT   MOD_RES     522    522       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:7929427}.
FT   MOD_RES     530    530       Phosphotyrosine; by CSK.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000269|PubMed:26936507,
FT                                ECO:0000269|PubMed:7525268}.
FT   LIPID         2      2       N-myristoyl glycine.
FT                                {ECO:0000269|PubMed:7525268}.
FT   VAR_SEQ     117    117       T -> TRKVDVR (in isoform 2).
FT                                {ECO:0000303|PubMed:2681803}.
FT                                /FTId=VSP_012134.
FT   VARIANT     176    176       L -> F (in dbSNP:rs6018260).
FT                                /FTId=VAR_051699.
FT   VARIANT     237    237       A -> T (in dbSNP:rs34881773).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041830.
FT   VARIANT     527    527       E -> K (in THC6; increased protein
FT                                tyrosine kinase activity; increased
FT                                autophosphorylation at Y-419; causes
FT                                defective megakaryopoiesis associated
FT                                with increased overall tyrosine
FT                                phosphorylation in megakaryocytes).
FT                                {ECO:0000269|PubMed:26936507}.
FT                                /FTId=VAR_076919.
FT   MUTAGEN     298    298       K->M: Kinase inactive. Abolishes
FT                                ubiquitination promoted by CBLC.
FT                                {ECO:0000269|PubMed:14661060}.
FT   STRAND       87     93       {ECO:0000244|PDB:1FMK}.
FT   STRAND       99    102       {ECO:0000244|PDB:1FMK}.
FT   STRAND      110    114       {ECO:0000244|PDB:1FMK}.
FT   STRAND      118    126       {ECO:0000244|PDB:1FMK}.
FT   TURN        127    129       {ECO:0000244|PDB:1FMK}.
FT   STRAND      132    136       {ECO:0000244|PDB:1FMK}.
FT   HELIX       137    139       {ECO:0000244|PDB:1FMK}.
FT   STRAND      140    142       {ECO:0000244|PDB:1FMK}.
FT   HELIX       146    148       {ECO:0000244|PDB:1FMK}.
FT   STRAND      152    154       {ECO:0000244|PDB:1FMK}.
FT   HELIX       158    165       {ECO:0000244|PDB:1FMK}.
FT   STRAND      167    170       {ECO:0000244|PDB:1SHD}.
FT   STRAND      174    179       {ECO:0000244|PDB:1FMK}.
FT   STRAND      181    183       {ECO:0000244|PDB:1FMK}.
FT   STRAND      187    195       {ECO:0000244|PDB:1FMK}.
FT   TURN        196    198       {ECO:0000244|PDB:1FMK}.
FT   STRAND      199    209       {ECO:0000244|PDB:1FMK}.
FT   STRAND      211    213       {ECO:0000244|PDB:2SRC}.
FT   STRAND      215    218       {ECO:0000244|PDB:1FMK}.
FT   STRAND      221    225       {ECO:0000244|PDB:1FMK}.
FT   HELIX       226    233       {ECO:0000244|PDB:1FMK}.
FT   STRAND      240    242       {ECO:0000244|PDB:1FMK}.
FT   STRAND      256    259       {ECO:0000244|PDB:1FMK}.
FT   HELIX       267    269       {ECO:0000244|PDB:1FMK}.
FT   STRAND      270    278       {ECO:0000244|PDB:1FMK}.
FT   STRAND      283    289       {ECO:0000244|PDB:1FMK}.
FT   TURN        290    292       {ECO:0000244|PDB:1FMK}.
FT   STRAND      293    299       {ECO:0000244|PDB:1FMK}.
FT   TURN        302    304       {ECO:0000244|PDB:2BDF}.
FT   HELIX       307    319       {ECO:0000244|PDB:1FMK}.
FT   STRAND      328    332       {ECO:0000244|PDB:1FMK}.
FT   STRAND      334    336       {ECO:0000244|PDB:1FMK}.
FT   STRAND      338    341       {ECO:0000244|PDB:1FMK}.
FT   HELIX       349    353       {ECO:0000244|PDB:1FMK}.
FT   HELIX       355    358       {ECO:0000244|PDB:1FMK}.
FT   HELIX       363    382       {ECO:0000244|PDB:1FMK}.
FT   HELIX       392    394       {ECO:0000244|PDB:1FMK}.
FT   STRAND      395    397       {ECO:0000244|PDB:1FMK}.
FT   HELIX       399    401       {ECO:0000244|PDB:1FMK}.
FT   STRAND      403    405       {ECO:0000244|PDB:1FMK}.
FT   HELIX       410    413       {ECO:0000244|PDB:2SRC}.
FT   HELIX       417    420       {ECO:0000244|PDB:2SRC}.
FT   TURN        423    426       {ECO:0000244|PDB:1Y57}.
FT   HELIX       429    431       {ECO:0000244|PDB:1FMK}.
FT   HELIX       434    439       {ECO:0000244|PDB:1FMK}.
FT   HELIX       444    459       {ECO:0000244|PDB:1FMK}.
FT   TURN        460    462       {ECO:0000244|PDB:1FMK}.
FT   HELIX       471    479       {ECO:0000244|PDB:1FMK}.
FT   HELIX       492    501       {ECO:0000244|PDB:1FMK}.
FT   HELIX       506    508       {ECO:0000244|PDB:1FMK}.
FT   HELIX       512    520       {ECO:0000244|PDB:1FMK}.
FT   TURN        521    523       {ECO:0000244|PDB:1FMK}.
SQ   SEQUENCE   536 AA;  59835 MW;  C1908084683E5DE8 CRC64;
     MGSNKSKPKD ASQRRRSLEP AENVHGAGGG AFPASQTPSK PASADGHRGP SAAFAPAAAE
     PKLFGGFNSS DTVTSPQRAG PLAGGVTTFV ALYDYESRTE TDLSFKKGER LQIVNNTEGD
     WWLAHSLSTG QTGYIPSNYV APSDSIQAEE WYFGKITRRE SERLLLNAEN PRGTFLVRES
     ETTKGAYCLS VSDFDNAKGL NVKHYKIRKL DSGGFYITSR TQFNSLQQLV AYYSKHADGL
     CHRLTTVCPT SKPQTQGLAK DAWEIPRESL RLEVKLGQGC FGEVWMGTWN GTTRVAIKTL
     KPGTMSPEAF LQEAQVMKKL RHEKLVQLYA VVSEEPIYIV TEYMSKGSLL DFLKGETGKY
     LRLPQLVDMA AQIASGMAYV ERMNYVHRDL RAANILVGEN LVCKVADFGL ARLIEDNEYT
     ARQGAKFPIK WTAPEAALYG RFTIKSDVWS FGILLTELTT KGRVPYPGMV NREVLDQVER
     GYRMPCPPEC PESLHDLMCQ CWRKEPEERP TFEYLQAFLE DYFTSTEPQY QPGENL
//
